TrialSite News recently reported on the Ebola vaccine clinical trial led locally Democratic Republic of Congo’s National Institute for Biomedical Research. Their director, Jean-Jacques Muyembe, is acknowledged as one of the top Ebola researchers worldwide. He was described by Lancet as “the Ebola Hunter.”
Recently, Regeneron’s REGN-EB3 and a monoclonal antibody developed by the NIH called mAb114, both harvested from survivor’s of Ebola infections, evidence promise as treatments for the deadly Ebola virus. The treatments will now be offered to patients in the Democratic Republic of Congo (DRC). The therapies were so successful the trials were halted so that the focus can now be on treating Ebola patients.
The successful new investigational Ebola vaccines are part of a workstream of Ebola research Muyembe has been deeply involved with since the earlier Ebola outbreak back in 1995. During that time Muyembe and colleagues were treating patients with a combination of antibodies from Ebola survivors. Some time later NIAID investigators leveraged this work—studying the investigational product and consequently isolating the antibodies from those survivors which ultimately led to mAb114.
Dr. Muyembe was first introduced to Ebola at a Catholic mission hospital in Yambuku, a remote village in northern Congo. He targeted this deadly disease since, reports the Daily Nation.
TrialSite News celebrates Dr. Jean-Jacques Muyembe and the significant progress made to save lives in this part of the world.
Lead Research/InvestigatorSource: World Health Organization